Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: Structural exploration

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5999-6011

  Valant, Céline ^a   Maillet, Emeline ^c   Bourguignon, Jean Jacques ^a   Bucher, Bernard ^b   Utard, Valérie ^c   Galzi, Jean Luc ^c   Hibert, Marcel ^a  

^a Faculté de Pharmacie   (France)

^b Faculté de Pharmacie   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BENZYL (2 NAPHTHYLMETHYL) AMINO] BUTYRONITRILE; 5 [BENZYL2 NAPHTHYLMETHYL) AMINO] PENTANOIC ACID; [2 BROMOBENZYL (2 NAPHTHYLMETHYL) AMINO] ACETONITRILE; [4 BROMOBENZYL (2 NAPHTHYLMETHYL) AMINO] ACETONITRILE; [4 IODOBENZYL (2 NAPHTHYLMETHYL) AMINO] ACETONITRILE; [4 METHOXYBENZYL (2 NAPHTHYLMETHYL) AMINO] ACETONITRILE; [4 PHENETHYLBENZYL (2 NAPHTHYLMETHYL) AMINO] ACETONITRILE; [BENZYL (1H INDOL 3 YLMETHYL) AMINO] ACTONITRILE; [BENZYL (2 NAPHTHYLMETHYL) AMINO] 2 HYDROXYETHYL ACETATE; [BENZYL (2 NAPHTHYLMETHYL) AMINO] ACETIC ACID; [BENZYL (2 NAPHTHYLMETHYL) AMINO] ETHYLMORPHOLINE ACETATE; [BENZYL (2 NAPHTHYLMETHYL) AMINO] HEXADECANOYL ACETATE; [BENZYL (2 NAPHTHYLMETHYL) AMINO] PHENETHYLE ACETATE; [BENZYL (2 NAPHTHYLMETHYL) PROPARGYL] AMINE; [BENZYL (3 CHLOROBENZYL) AMINO] ACETONITRILE; [BENZYL (4 CHLOROBENZYL) AMINO] ACETONITRILE; [BENZYL (4 METHOXYBENZYL) AMINO] ACETONITRILE; [BENZYL (QUINOLIN 2 YLMETHYL) AMINO] ACETONITRILE; [BENZYL [ 3 PHENYLPROP 2 EN 1 YL] AMINO] ACETONITRILE; [BENZYL [4 (TRIFLUOROMETHYL) BENZYL] AMINO] ACETONITRILE; ACETONITRILE DERIVATIVE; BENZYL DERIVATIVE; CYCLIC AMP; ETHYL 5 [BENZYL (2 NAPHTHYLMETHYL) AMINO] PENTANOATE; N BENZYL,N (2 NAPHTHYLMETHYL)AMINO ACETONITRILE; N ETHYL [BENZYL (2 NAPHTHYLMETHYL) AMINE] ACETATE; NAPHTHALENE; NEUROKININ 2 RECEPTOR; NEUROKININ A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; DRUG BINDING; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; CALCIUM SIGNALING; CYCLIC AMP; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HYDROCARBONS, AROMATIC; LIGANDS; NEUROKININ A; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROKININ-2; SIGNAL TRANSDUCTION;

EID: 70349635706     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900671k     Document Type: Article

References (33)

1. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discovery 2002, 1, 198-210.
2. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51.
3. (a) Forster, T. Energiewanderung und fluoreszenz. Naturwissenschaften 1946, 6, 166-175.
4. (b) Clegg, R. M. Fluorescence energy transfer. Curr. Opin. Biotechnol. 1995, 6, 103-110.
5. Vollmer, J. Y.; Alix, P.; Chollet, A.; Takeda, K.; Galzi, J. L. Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors. J. Biol. Chem. 1999, 274, 37915-37922.
6. Zimmer, M. Green fluorescent protein (GFP): applications, structure and related photophysical behaviour. Chem. Rev. 2002, 102, 759-781.
7. Palanche, T.; Ilien, B.; Zoffmann, S.; Reck, M. P.; Bucher, B.; Edelstein, S. J.; Galzi, J. L. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 2001, 276, 34853-34861.
8. Ilien, B.; Franchet, C.; Bernard, P.; Morisset, S.; Weill, C. O.; Bourguignon, J. J.; Hibert, M.; Galzi, J. L. Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. J. Neurochem. 2003, 85, 768-778.
9. Maillet, E. L.; Pellegrini, N.; Valant, C.; Bucher, B.; Hibert, M.; Bourguignon, J. J.; Galzi, J. L. A novel conformation specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 2007, 21, 2124-2134.
10. Galzi, J. L.; Hibert, M.; Bourguignon, J. J.; Maillet, E. Method for isolating an allosteric effector of a receptor. WO Patent 03107004, December, 2003.
11. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein coupled receptor. Science 2000, 289, 739-745. (Pubitemid 30650186)
12. Bhogal, N.; Donnelly, D.; Findlay, J. B. The ligand binding site of theneurokinin 2 receptor. Site-directedmutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor. J. Biol. Chem. 1994, 269, 27269-27274.
13. Labrou, N. E.; Bhogal, N.; Hurrell, C. R.; Findlay, J. B. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. J. Biol. Chem. 2001, 276, 37944-37949
14. Milligan, G.; Smith, N. J. Allosteric modulation of heterodimeric G-protein coupled receptors. Trends Pharmacol. Sci. 2007, 28, 615-620
15. Milligan, G.; Bouvier, M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J. 2005, 272, 2914-2925. (Pubitemid 40904680)
16. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S.; Thian, F.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W.; Kobilka, B.; Stevens, R. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318, 1258-1265. (Pubitemid 350172884)
17. Warne, T.; Maria, J.; Serrano-Vega, M.; Baker, J.; Moukhametzianov, R; Edwards, P.; Henderson, R.; Leslie, A.; Tate, C.; Schertler, G. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 2008, 454, 486-491.
18. Veli-Pekka Jaakola, V.; Griffith, M.; Hanson, M.; Cherezov, V.; Chien, E.; Lane, R.; IJzerman, A.; Stevens, R. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science 2008, 322, 1211-1217.
19. Springael, J.-Y.; Urizar, E.; Costagliola, S.; Vassart, G.; Parmentier, M. Allosteric properties of G protein coupled receptor oligomers. Pharmacol. Ther. 2007, 115, 410-418.
20. Adham, N.; Ellerbrock, B.; Hartig, P.; Weinshank, R. L.; Branchek, T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol. Pharmacol. 1993, 43, 427-433.
21. Whaley, B. S.; Yuan, N.; Birnbaumer, L.; Clark, R. B.; Barber, R. Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol. Pharmacol. 1994, 45, 481-489.
22. Soudijn, W.; van Wijngaarden, I.; IJzerman, A. Allosteric modulation of G protein coupled receptors: perspectives and recent developments. Drug Discovery Today 2004, 9, 752-758.
23. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 2007, 28, 382-389.
24. Schwartz, T.; Holst, B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol. Sci. 2007, 28, 367-373.
25. Neubig, R. R.; Spedding, M.; Kenakin, T.; Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 2003, 55, 597-606.
26. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1-13.
27. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 1995, 16, 232-238.
28. Hermans, E. Biochemical and pharmacological control of the multiplicity of coupling ofGprotein coupled receptors. Pharmacol. Ther. 2003, 99, 25-44.
29. Tateyama, M.; Kubo, Y. Dual signalling is differentially affected by different active states of the metabotropic glutamate receptor 1r. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 1124-1128.
30. Aurelio, L.; Valant, C.; Flynn, B.; Sexton, P.; Christopoulos, A.; Scammells, P. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4 substituted 2-amino- 3-bezoylthiophenes. J. Med. Chem. 2009, 52, 4543-4547.
31. Lecat, S.; Bucher, B.; Mely, Y.; Galzi, J. L. Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J. Biol. Chem. 2002, 277, 42034-42048.
32. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289, 739-745.
33. Topiol, S.; Sabioa, M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem. Pharmacol. 2009, 38, 11-20.